C6A6
A neo-epitope fragment of the α6 chain of type VI collagen, enabling non-invasive monitoring of dermal extracellular matrix remodeling and fibroblast activation in inflammatory skin disorders.
Key features and values
- Quantifies specific fragments of the α6 chain of type VI collagen.
- Reflects dermal extracellular matrix remodeling associated with fibroblast activation.
- Provides a non-invasive measure of tissue remodeling in inflammatory skin conditions.
- Supports monitoring of disease progression and response to therapies targeting extracellular matrix remodeling.
- Applicable in research on dermatological diseases characterized by fibroblast-driven tissue remodeling.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
Description
The C6A6 biomarker assay measures specific neo-epitope fragments of the α6 chain of type VI collagen, serving as an indicator of dermal extracellular matrix remodeling and fibroblast activation in inflammatory skin disorders. This non-invasive assay provides insights into pathological tissue remodeling processes, particularly in conditions such as atopic dermatitis, psoriasis, and systemic lupus erythematosus. By quantifying collagen degradation products associated with fibroblast activity, the C6A6 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of skin tissue remodeling. It serves as a valuable tool in both clinical and research settings for assessing the dynamics of dermal extracellular matrix turnover.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
